x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Minnesota | 41-0886515 |
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number) |
1031 Mendota Heights Road St. Paul, Minnesota | 55120 |
(Address of Principal Executive Offices) | (Zip Code) |
Large Accelerated Filer | x | Accelerated Filer | ¨ | |||
Non-Accelerated Filer | ¨ (Do not check if a smaller reporting company) | Smaller Reporting Company | ¨ |
Page | |
October 29, 2016 | April 30, 2016 | ||||||
(Unaudited) | |||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 110,387 | $ | 137,453 | |||
Receivables, net of allowance for doubtful accounts | 822,734 | 796,693 | |||||
Inventory | 795,454 | 722,140 | |||||
Prepaid expenses and other current assets | 104,257 | 91,255 | |||||
Total current assets | 1,832,832 | 1,747,541 | |||||
Property and equipment, net | 303,342 | 293,315 | |||||
Long-term receivables, net | 97,114 | 88,248 | |||||
Goodwill | 812,419 | 816,592 | |||||
Identifiable intangibles, net | 479,977 | 509,297 | |||||
Other | 64,684 | 65,811 | |||||
Total assets | $ | 3,590,368 | $ | 3,520,804 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 545,366 | $ | 566,253 | |||
Accrued payroll expense | 69,271 | 75,448 | |||||
Other accrued liabilities | 148,407 | 151,134 | |||||
Current maturities of long-term debt | 20,625 | 16,500 | |||||
Borrowings on revolving credit | 163,000 | 20,000 | |||||
Total current liabilities | 946,669 | 829,335 | |||||
Long-term debt | 1,010,211 | 1,022,155 | |||||
Other non-current liabilities | 227,436 | 227,568 | |||||
Total liabilities | 2,184,316 | 2,079,058 | |||||
Stockholders’ equity: | |||||||
Common stock | 982 | 991 | |||||
Additional paid-in capital | 57,542 | 48,477 | |||||
Accumulated other comprehensive loss | (101,352 | ) | (67,964 | ) | |||
Retained earnings | 1,517,796 | 1,529,158 | |||||
Unearned ESOP shares | (68,916 | ) | (68,916 | ) | |||
Total stockholders’ equity | 1,406,052 | 1,441,746 | |||||
Total liabilities and stockholders’ equity | $ | 3,590,368 | $ | 3,520,804 |
Three Months Ended | Six Months Ended | ||||||||||||||
October 29, 2016 | October 31, 2015 | October 29, 2016 | October 31, 2015 | ||||||||||||
Net sales | $ | 1,418,241 | $ | 1,389,210 | $ | 2,750,677 | $ | 2,532,080 | |||||||
Cost of sales | 1,099,281 | 1,058,311 | 2,114,539 | 1,912,937 | |||||||||||
Gross profit | 318,960 | 330,899 | 636,138 | 619,143 | |||||||||||
Operating expenses | 239,157 | 247,436 | 490,919 | 473,503 | |||||||||||
Operating income from continuing operations | 79,803 | 83,463 | 145,219 | 145,640 | |||||||||||
Other income (expense): | |||||||||||||||
Other income, net | 1,622 | 954 | 3,986 | 1,624 | |||||||||||
Interest expense | (10,097 | ) | (17,154 | ) | (20,259 | ) | (29,297 | ) | |||||||
Income from continuing operations before taxes | 71,328 | 67,263 | 128,946 | 117,967 | |||||||||||
Income tax expense | 25,572 | 24,700 | 44,284 | 55,093 | |||||||||||
Net income from continuing operations | 45,756 | 42,563 | 84,662 | 62,874 | |||||||||||
Net income (loss) from discontinued operations | — | (7,142 | ) | — | 2,250 | ||||||||||
Net income | $ | 45,756 | $ | 35,421 | $ | 84,662 | $ | 65,124 | |||||||
Basic earnings (loss) per share: | |||||||||||||||
Continuing operations | $ | 0.48 | $ | 0.43 | $ | 0.89 | $ | 0.64 | |||||||
Discontinued operations | — | (0.07 | ) | — | 0.02 | ||||||||||
Net basic earnings per share | $ | 0.48 | $ | 0.36 | $ | 0.89 | $ | 0.66 | |||||||
Diluted earnings (loss) per share: | |||||||||||||||
Continuing operations | $ | 0.48 | $ | 0.43 | $ | 0.88 | $ | 0.63 | |||||||
Discontinued operations | — | (0.07 | ) | — | 0.02 | ||||||||||
Net diluted earnings per share | $ | 0.48 | $ | 0.36 | $ | 0.88 | $ | 0.65 | |||||||
Weighted average shares: | |||||||||||||||
Basic | 95,290 | 98,525 | 95,510 | 98,981 | |||||||||||
Diluted | 95,904 | 99,185 | 96,138 | 99,674 | |||||||||||
Dividends declared per common share | $ | 0.24 | $ | 0.22 | $ | 0.48 | $ | 0.44 | |||||||
Comprehensive income | |||||||||||||||
Net income | $ | 45,756 | $ | 35,421 | $ | 84,662 | $ | 65,124 | |||||||
Foreign currency translation gain (loss) | (14,001 | ) | 6,941 | (34,258 | ) | (4,334 | ) | ||||||||
Cash flow hedges, net of tax | 437 | 437 | 870 | 1,054 | |||||||||||
Comprehensive income | $ | 32,192 | $ | 42,799 | $ | 51,274 | $ | 61,844 |
Six Months Ended | |||||||
October 29, 2016 | October 31, 2015 | ||||||
Operating activities: | |||||||
Net income | $ | 84,662 | $ | 65,124 | |||
Net income from discontinued operations | — | 2,250 | |||||
Net income from continuing operations | 84,662 | 62,874 | |||||
Adjustments to reconcile net income from continuing operations to net cash used in operating activities: | |||||||
Depreciation | 18,010 | 16,791 | |||||
Amortization | 23,997 | 21,609 | |||||
Bad debt expense | 58 | 5,674 | |||||
Non-cash employee compensation | 14,693 | 13,541 | |||||
Accelerated amortization of debt issuance costs on early retirement of debt | — | 5,153 | |||||
Excess tax benefits from stock-based compensation | — | (1,686 | ) | ||||
Change in assets and liabilities, net of acquired | (196,726 | ) | (137,923 | ) | |||
Net cash used in operating activities- continuing operations | (55,306 | ) | (13,967 | ) | |||
Net cash used in operating activities- discontinued operations | — | (38,985 | ) | ||||
Net cash used in operating activities | (55,306 | ) | (52,952 | ) | |||
Investing activities: | |||||||
Additions to property and equipment | (29,377 | ) | (40,978 | ) | |||
Acquisitions and equity investments, net of cash assumed | — | (1,105,229 | ) | ||||
Proceeds from sale of securities | — | 48,744 | |||||
Other investing activities | 23,115 | — | |||||
Net cash used in investing activities- continuing operations | (6,262 | ) | (1,097,463 | ) | |||
Net cash provided by investing activities- discontinued operations | — | 715,430 | |||||
Net cash used in investing activities | (6,262 | ) | (382,033 | ) | |||
Financing activities: | |||||||
Dividends paid | (47,655 | ) | (45,356 | ) | |||
Repurchases of common stock | (50,000 | ) | (160,579 | ) | |||
Proceeds from issuance of long-term debt | — | 1,000,000 | |||||
Debt issuance costs | — | (11,600 | ) | ||||
Retirement of long-term debt | (8,250 | ) | (674,125 | ) | |||
Draw on revolver | 143,000 | 80,000 | |||||
Other financing activities | 974 | 2,894 | |||||
Net cash provided by financing activities | 38,069 | 191,234 | |||||
Effect of exchange rate changes on cash | (3,567 | ) | (8,058 | ) | |||
Net change in cash and cash equivalents | (27,066 | ) | (251,809 | ) | |||
Cash and cash equivalents at beginning of period | 137,453 | 347,260 | |||||
Cash and cash equivalents at end of period | $ | 110,387 | $ | 95,451 |
Three Months Ended | Six Months Ended | ||||||||||
October 29, 2016 | October 31, 2015 | October 29, 2016 | October 31, 2015 | ||||||||
Denominator for basic earnings per share – weighted average shares | 95,290 | 98,525 | 95,510 | 98,981 | |||||||
Effect of dilutive securities – stock options, restricted stock and stock purchase plans | 614 | 660 | 628 | 693 | |||||||
Denominator for diluted earnings per share – weighted average shares | 95,904 | 99,185 | 96,138 | 99,674 |
Derivative type | Classification | October 29, 2016 | April 30, 2016 | |||||
Assets: | ||||||||
Interest rate cap agreements | Other noncurrent assets | $ | 790 | $ | 816 | |||
Liabilities: | ||||||||
Interest rate cap agreements | Other noncurrent liabilities | 790 | 816 |
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income (Effective Portion) | ||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||
Derivatives in cash flow hedging relationships | Income statement location | October 29, 2016 | October 31, 2015 | October 29, 2016 | October 31, 2015 | |||||||||||||
Interest rate swap | Interest expense | $ | (702 | ) | $ | (703 | ) | $ | (1,397 | ) | $ | (1,405 | ) |
October 29, 2016 | |||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||
Assets: | |||||||||||||||
Cash equivalents | $ | 3,506 | $ | 3,506 | $ | — | $ | — | |||||||
Deferred purchase price receivable | 118,059 | — | — | 118,059 | |||||||||||
Derivative instruments | 790 | — | 790 | — | |||||||||||
Total assets | $ | 122,355 | $ | 3,506 | $ | 790 | $ | 118,059 | |||||||
Liabilities: | |||||||||||||||
Derivative instruments | $ | 790 | $ | — | $ | 790 | $ | — |
April 30, 2016 | |||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||
Assets: | |||||||||||||||
Cash equivalents | $ | 14,609 | $ | 14,609 | $ | — | $ | — | |||||||
Deferred purchase price receivable | 108,837 | — | — | 108,837 | |||||||||||
Derivative instruments | 816 | — | 816 | — | |||||||||||
Total assets | $ | 124,262 | $ | 14,609 | $ | 816 | $ | 108,837 | |||||||
Liabilities: | |||||||||||||||
Derivative instruments | $ | 816 | $ | — | $ | 816 | $ | — |
Three Months Ended | Six Months Ended | ||||||||||||||
October 29, 2016 | October 31, 2015 | October 29, 2016 | October 31, 2015 | ||||||||||||
Net sales | |||||||||||||||
Dental | $ | 601,553 | $ | 601,322 | $ | 1,156,568 | $ | 1,176,439 | |||||||
Animal Health | 807,146 | 774,453 | 1,569,777 | 1,331,750 | |||||||||||
Corporate | 9,542 | 13,435 | 24,332 | 23,891 | |||||||||||
Consolidated net sales | $ | 1,418,241 | $ | 1,389,210 | $ | 2,750,677 | $ | 2,532,080 | |||||||
Operating income (loss) from continuing operations | |||||||||||||||
Dental | $ | 77,043 | $ | 74,094 | $ | 137,338 | $ | 141,346 | |||||||
Animal Health | 21,854 | 25,177 | 36,683 | 38,149 | |||||||||||
Corporate | (19,094 | ) | (15,808 | ) | (28,802 | ) | (33,855 | ) | |||||||
Consolidated operating income from continuing operations | $ | 79,803 | $ | 83,463 | $ | 145,219 | $ | 145,640 |
October 29, 2016 | April 30, 2016 | ||||||
Total assets | |||||||
Dental | $ | 930,541 | $ | 994,113 | |||
Animal Health | 2,148,059 | 2,064,302 | |||||
Corporate | 511,768 | 462,389 | |||||
Total assets | $ | 3,590,368 | $ | 3,520,804 |
Three Months Ended | Six Months Ended | ||||||||||||||
October 29, 2016 | October 31, 2015 | October 29, 2016 | October 31, 2015 | ||||||||||||
Net sales | |||||||||||||||
Consumable | $ | 1,112,232 | $ | 1,087,489 | $ | 2,188,453 | $ | 1,982,796 | |||||||
Equipment and software | 217,194 | 207,809 | 378,140 | 361,292 | |||||||||||
Other | 88,815 | 93,912 | 184,084 | 187,992 | |||||||||||
Consolidated net sales | $ | 1,418,241 | $ | 1,389,210 | $ | 2,750,677 | $ | 2,532,080 |
Cash Flow Hedges | Currency Translation Adjustment | Total | |||||||||
AOCL at April 30, 2016 | $ | (16,734 | ) | $ | (51,230 | ) | $ | (67,964 | ) | ||
Other comprehensive loss before reclassifications | — | (34,258 | ) | (34,258 | ) | ||||||
Amounts reclassified from AOCL | 870 | — | 870 | ||||||||
AOCL at October 29, 2016 | $ | (15,864 | ) | $ | (85,488 | ) | $ | (101,352 | ) |
Three Months Ended | |||||
October 29, 2016 | October 31, 2015 | ||||
Net sales | 100.0 | % | 100.0 | % | |
Cost of sales | 77.5 | 76.2 | |||
Gross profit | 22.5 | 23.8 | |||
Operating expenses | 16.9 | 17.8 | |||
Operating income from continuing operations | 5.6 | 6.0 | |||
Other income (expense) | (0.6 | ) | (1.2 | ) | |
Income from continuing operations before taxes | 5.0 | 4.8 | |||
Income tax expense | 1.8 | 1.7 | |||
Net income from continuing operations | 3.2 | % | 3.1 | % |
Six Months Ended | |||||
October 29, 2016 | October 31, 2015 | ||||
Net sales | 100.0 | % | 100.0 | % | |
Cost of sales | 76.9 | 75.5 | |||
Gross profit | 23.1 | 24.5 | |||
Operating expenses | 17.8 | 18.7 | |||
Operating income from continuing operations | 5.3 | 5.8 | |||
Other income (expense) | (0.6 | ) | (1.1 | ) | |
Income from continuing operations before taxes | 4.7 | 4.7 | |||
Income tax expense | 1.6 | 2.2 | |||
Net income from continuing operations | 3.1 | % | 2.5 | % |
Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number of Shares That May Yet Be Purchased Under the Plan | |||||||||
July 31, 2016 to August 27, 2016 | — | $ | — | — | 15,966,185 | |||||||
August 28, 2016 to September 24, 2016 | 404,493 | 46.02 | 404,493 | 15,561,692 | ||||||||
September 25, 2016 to October 29, 2016 | 139,048 | 45.91 | 139,048 | 15,422,644 | ||||||||
543,541 | $ | 45.99 | 543,541 | 15,422,644 |
PATTERSON COMPANIES, INC. | |||
(Registrant) | |||
Dated: December 7, 2016 | |||
By: | /s/ Ann B. Gugino | ||
Ann B. Gugino | |||
Executive Vice President, Chief Financial Officer and Treasurer | |||
(Principal Financial Officer and Principal Accounting Officer) |
Exhibit No. | Exhibit Description | |
31.1 | Certification of the Chief Executive Officer pursuant to Rules 13a-4(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2 | Certification of the Chief Financial Officer pursuant to Rule 13a-4(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1 | Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
32.2 | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
101 | Financials in XBRL format. |
/s/ Scott P. Anderson |
Scott P. Anderson |
President and Chief Executive Officer |
/s/ Ann B. Gugino |
Ann B. Gugino |
Executive Vice President, Chief Financial Officer and Treasurer |
/s/ Scott P. Anderson |
Scott P. Anderson |
President and Chief Executive Officer |
December 7, 2016 |
/s/ Ann B. Gugino |
Ann B. Gugino |
Executive Vice President, Chief Financial Officer and Treasurer |
December 7, 2016 |
Document and Entity Information - shares |
6 Months Ended | |
---|---|---|
Oct. 29, 2016 |
Dec. 02, 2016 |
|
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Oct. 29, 2016 | |
Document Fiscal Year Focus | 2017 | |
Document Fiscal Period Focus | Q2 | |
Trading Symbol | PDCO | |
Entity Registrant Name | PATTERSON COMPANIES, INC. | |
Entity Central Index Key | 0000891024 | |
Current Fiscal Year End Date | --04-29 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 97,909,000 |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Oct. 29, 2016 |
Oct. 31, 2015 |
Oct. 29, 2016 |
Oct. 31, 2015 |
|
Income Statement [Abstract] | ||||
Net sales | $ 1,418,241 | $ 1,389,210 | $ 2,750,677 | $ 2,532,080 |
Cost of sales | 1,099,281 | 1,058,311 | 2,114,539 | 1,912,937 |
Gross profit | 318,960 | 330,899 | 636,138 | 619,143 |
Operating expenses | 239,157 | 247,436 | 490,919 | 473,503 |
Operating income from continuing operations | 79,803 | 83,463 | 145,219 | 145,640 |
Other income (expense): | ||||
Other income, net | 1,622 | 954 | 3,986 | 1,624 |
Interest expense | (10,097) | (17,154) | (20,259) | (29,297) |
Income from continuing operations before taxes | 71,328 | 67,263 | 128,946 | 117,967 |
Income tax expense | 25,572 | 24,700 | 44,284 | 55,093 |
Net income from continuing operations | 45,756 | 42,563 | 84,662 | 62,874 |
Net income (loss) from discontinued operations | 0 | (7,142) | 0 | 2,250 |
Net income | $ 45,756 | $ 35,421 | $ 84,662 | $ 65,124 |
Basic earnings (loss) per share: | ||||
Continuing operations (in USD per share) | $ 0.48 | $ 0.43 | $ 0.89 | $ 0.64 |
Discontinued operations (in USD per share) | 0.00 | (0.07) | 0.00 | 0.02 |
Net basic earnings per share (in USD per share) | 0.48 | 0.36 | 0.89 | 0.66 |
Diluted earnings (loss) per share: | ||||
Continuing operations (in USD per share) | 0.48 | 0.43 | 0.88 | 0.63 |
Discontinued operations (in USD per share) | 0.00 | (0.07) | 0.00 | 0.02 |
Net diluted earnings per share (in USD per share) | $ 0.48 | $ 0.36 | $ 0.88 | $ 0.65 |
Weighted average shares: | ||||
Basic (in shares) | 95,290 | 98,525 | 95,510 | 98,981 |
Diluted (in shares) | 95,904 | 99,185 | 96,138 | 99,674 |
Dividends declared per common share (in USD per share) | $ 0.24 | $ 0.22 | $ 0.48 | $ 0.44 |
Comprehensive income | ||||
Net income | $ 45,756 | $ 35,421 | $ 84,662 | $ 65,124 |
Foreign currency translation gain (loss) | (14,001) | 6,941 | (34,258) | (4,334) |
Cash flow hedges, net of tax | 437 | 437 | 870 | 1,054 |
Comprehensive income | $ 32,192 | $ 42,799 | $ 51,274 | $ 61,844 |
General |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General | General Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of Patterson Companies, Inc. (referred to herein as "Patterson" or in the first person notations "we," "our," and "us") as of October 29, 2016, and our results of operations and cash flows for the periods ended October 29, 2016 and October 31, 2015. Such adjustments are of a normal recurring nature. The results of operations for the periods ended October 29, 2016 and October 31, 2015 are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the financial statements included in our 2016 Annual Report on Form 10-K filed on June 29, 2016. The unaudited condensed consolidated financial statements include the assets and liabilities of PDC Funding Company, LLC ("PDC Funding") and PDC Funding Company II, LLC ("PDC Funding II"), which are our wholly owned subsidiaries and separate legal entities formed under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities established to sell customer installment sale contracts to outside financial institutions in the normal course of their business. The assets of PDC Funding and PDC Funding II would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding or PDC Funding II. Fiscal Year End We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. The second quarter of fiscal 2017 and 2016 represents the 13 weeks ended October 29, 2016 and the 13 weeks ended October 31, 2015, respectively. The six months ended October 29, 2016 and October 31, 2015 included 26 and 27 weeks, respectively. Fiscal 2017 will include 52 weeks and fiscal 2016 included 53 weeks of operations. Comprehensive Income Comprehensive income is computed as net income including certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income are foreign currency translation adjustments and the effective portion of cash flow hedges, net of tax. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S. The income tax expense related to cash flow hedges was $265 and $265 for the three months ended October 29, 2016 and October 31, 2015, respectively. The income tax expense related to cash flow hedges was $527 and $350 for the six months ended October 29, 2016 and October 31, 2015, respectively. Earnings Per Share The following table sets forth the computation of the weighted average shares outstanding used to calculate basic and diluted earnings per share ("EPS"):
Potentially dilutive securities representing 1,453 and 1,218 shares for the three and six months ended October 29, 2016, respectively, and 899 and 899 shares for the three and six months ended October 31, 2015, respectively, were excluded from the calculation of diluted earnings per share because their effects were anti-dilutive. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" and issued subsequent amendments to the initial guidance in August 2015, March 2016, April 2016 and May 2016 within ASU 2015-14, ASU 2016-08, ASU 2016-10 and ASU 2016-12, respectively. ASU No. 2014-09 supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of this pronouncement by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption is permitted, but not before the original effective date, which for annual periods was December 15, 2016. We are evaluating the impact of adopting this pronouncement. In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory." ASU 2015-11 requires inventory measured using any method other than LIFO or the retail inventory method to be subsequently measured at the lower of cost or net realizable value, rather than at the lower of cost or market. Subsequent measurement of inventory using the LIFO and retail inventory method is unchanged. We are required to adopt the new pronouncement in the first quarter of fiscal 2018, and plan to do so at that time. Early adoption is permitted. We are evaluating the effect of adopting this pronouncement, but do not, at this time, anticipate a material impact to our financial statements once implemented. In January 2016, the FASB issued ASU No. 2016-01 "Financial Instruments- Recognition and Measurement of Financial Assets and Financial Liabilities (Subtopic 825-10)", which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments, including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. We are required to adopt the ASU No. 2016-01 in the first quarter of fiscal 2019, with early adoption permitted. We are evaluating the impact of adopting this pronouncement. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)," which requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases, as well as requires additional qualitative and quantitative disclosures. We are required to adopt ASU 2016-02 in the first quarter of fiscal 2020, with early adoption permitted. We are evaluating the impact of adopting this pronouncement. In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting." ASU No. 2016-09 eliminates the additional paid-in capital pool concept and requires that excess tax benefits and tax deficiencies be recorded in the income statement when awards are settled. ASU No. 2016-09 also addresses simplifications related to statement of cash flows classification, accounting for forfeitures, and minimum statutory tax withholding requirements. During the first quarter of fiscal 2017, we adopted ASU No. 2016-09. As a result of this adoption, we recognized $108 and $1,992 of excess tax benefits related to share-based payments in our provision for income taxes for the three and six months ended October 29, 2016, respectively. These items were historically recorded in additional paid-in capital. In addition, for the six months ended October 29, 2016, cash flows related to excess tax benefits are classified as an operating activity along with other income tax cash flows. Prior periods have not been adjusted. Cash paid on employees' behalf related to shares withheld for tax purposes continues to be classified as a financing activity. Our share-based compensation expense in each period continues to reflect estimated forfeitures. Reclassifications None. |
Discontinued Operations |
6 Months Ended |
---|---|
Oct. 29, 2016 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Discontinued Operations | Discontinued Operations In August 2015, we sold all of the outstanding shares of common stock of Patterson Medical Holdings, Inc., our wholly owned subsidiary responsible for our rehabilitation supply business ("Patterson Medical"), for $716,886 in cash to Madison Dearborn Partners. As additional consideration for the shares of Patterson Medical, we obtained a number of common units of the parent company of the buyer equal to 10% of the common units outstanding at closing. Unlike the other common units, these units will only become entitled to begin participating in distributions to the common unit holders at such time, if any, as the Madison Dearborn Partners’ investor cash inflows equal or exceed 2.5 times the Madison Dearborn Partners’ investor cash outflows. These units are non-transferable. In connection with the above described transaction, we also entered into a transition services agreement with our former subsidiary, pursuant to which Patterson Medical, as owned by Madison Dearborn Partners, is paying us to provide, among other things, certain information technology, distribution, facilities, finance, tax and treasury, and human resources services for up to 24 months after closing. We classified Patterson Medical’s results of operations as discontinued operations for all periods presented in the condensed consolidated statements of income. The operations and cash flows of Patterson Medical have been eliminated from our continuing operations, which were previously recorded as the rehabilitation supply reportable segment. Net sales from discontinued operations were $37,693 and $168,504 for the three and six months ending October 31, 2015, respectively. |
Customer Financing |
6 Months Ended |
---|---|
Oct. 29, 2016 | |
Receivables [Abstract] | |
Customer Financing | Customer Financing As a convenience to our customers, we offer several different financing alternatives, including a third party program and a Patterson-sponsored program. For the third party program, we act as a facilitator between the customer and the third party financing entity with no on-going involvement in the financing transaction. Under our sponsored program, equipment purchased by customers with strong credit may be financed up to a maximum of $1,000. We generally sell our customers’ financing contracts to outside financial institutions in the normal course of our business. These financing arrangements are accounted for as a sale of assets under the provisions of ASC 860, Transfers and Servicing. We currently have two arrangements under which we sell these contracts. First, we operate under an agreement to sell a portion of our equipment finance contracts to commercial paper conduits with The Bank of Tokyo-Mitsubishi UFJ, Ltd. ("BTMU") serving as the agent. We utilize PDC Funding to fulfill a requirement of participating in the commercial paper conduit. We receive the proceeds of the contracts upon sale to BTMU. At least 9% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with BTMU. The capacity under the agreement with BTMU at October 29, 2016 was $575,000. Second, we maintain an agreement with Fifth Third Bank ("Fifth Third") whereby the bank purchases customers’ financing contracts. PDC Funding II sells financing contracts to Fifth Third. We receive the proceeds of the contracts upon sale to Fifth Third. At least 10% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with Fifth Third. The capacity under the agreement with Fifth Third at October 29, 2016 was $100,000. We retain servicing responsibilities for the financing contracts under both arrangements, for which we are paid a servicing fee. The servicing fees we receive are considered adequate compensation for services rendered. Accordingly, no servicing asset or liability has been recorded. The portion of the purchase price for the receivables held by the conduits is deemed a deferred purchase price receivable, which is paid to the applicable special purpose entity as payments on the customers’ financing contracts are collected from customers. The difference between the carrying amount of the receivables sold under these programs and the sum of the cash and fair value of the deferred purchase price receivables received at time of transfer is recognized as a gain on sale of the related receivables and recorded in net sales in the consolidated statements of income. Expenses incurred related to customer financing activities were recorded in operating expenses in our condensed consolidated statements of income. During the three and six months ended October 29, 2016 we sold $62,663 and $172,257, respectively, of contracts under these arrangements. During the three and six months ended October 31, 2015 we sold $48,172 and $142,939, respectively, of contracts under these arrangements. We recorded net sales in the condensed consolidated statements of income of $4,331 and $14,516 during the three and six months ended October 29, 2016, respectively, related to these contracts sold. We recorded net sales in the condensed consolidated statements of income of $9,016 and $14,903 during the three and six months ended October 31, 2015, respectively, related to these contracts sold. Included in cash and cash equivalents in the condensed consolidated balance sheets are $22,809 and $27,186 as of October 29, 2016 and April 30, 2016, respectively, which represent cash collected from previously sold customer financing contracts that have not yet been settled. Included in current receivables in the condensed consolidated balance sheets are $82,591, net of unearned income of $2,334, and $87,406, net of unearned income of $1,768, as of October 29, 2016 and April 30, 2016, respectively, of finance contracts we have not yet sold. A total of $600,760 of finance contracts receivable sold under the arrangements was outstanding at October 29, 2016. The deferred purchase price under the arrangements was $118,059 and $108,837 as of October 29, 2016 and April 30, 2016, respectively. Since the internal financing program began in 1994, bad debt write-offs have amounted to less than 1% of the loans originated. The arrangements require us to maintain a minimum current ratio and maximum leverage ratio. We were in compliance with those covenants at October 29, 2016. |
Derivative Financial Instruments |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Financial Instruments | Derivative Financial Instruments We are a party to certain offsetting and identical interest rate cap agreements entered into to fulfill certain covenants of the equipment finance contract sale agreements. The interest rate cap agreements also provide a credit enhancement feature for the financing contracts sold by PDC Funding and PDC Funding II to the commercial paper conduit. The interest rate cap agreements are canceled and new agreements are entered into periodically to maintain consistency with the dollar maximum of the sale agreements and the maturity of the underlying financing contracts. As of October 29, 2016, PDC Funding had purchased an interest rate cap from a bank with a notional amount of $575,000 and a maturity date of November 2023. We sold an identical interest rate cap to the same bank. As of October 29, 2016, PDC Funding II had purchased an interest rate cap from a bank with a notional amount of $100,000 and a maturity date of July 2024. We sold an identical interest rate cap to the same bank. These interest rate cap agreements do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change as income or expense during the period in which the change occurs. In March 2008, we entered into two forward starting interest rate swap agreements, each with notional amounts of $100,000 and accounted for as cash flow hedges, to hedge interest rate fluctuations in anticipation of the issuance of the senior notes due fiscal 2015 and fiscal 2018. Upon issuance of the hedged debt, we settled the forward starting interest rate swap agreements and recorded a $1,000 increase, net of income taxes, to other comprehensive income (loss), which is being amortized as a reduction to interest expense over the life of the related debt. In January 2014, we entered into a forward interest rate swap agreement with a notional amount of $250,000 and accounted for as cash flow hedge, to hedge interest rate fluctuations in anticipation of refinancing the 5.17% senior notes due March 25, 2015. These notes were repaid on March 25, 2015 and replaced with new $250,000 3.48% senior notes due March 24, 2025. A cash payment of $29,003 was made in March 2015 to settle the interest rate swap. This amount is recorded in other comprehensive income (loss), net of tax, and is recognized as interest expense over the life of the related debt. The following presents the fair value of derivative instruments included in the condensed consolidated balance sheets:
The following table presents the pre-tax effect of derivative instruments in cash flow hedging relationships on the consolidated statements of income and other comprehensive income ("OCI"):
We recorded no effective portion of gains or losses on derivative instruments in cash flow hedging relationships in OCI during the current period. We recorded no ineffectiveness during the three and six month periods ended October 29, 2016 and October 31, 2015. As of October 29, 2016, the estimated pre-tax portion of accumulated other comprehensive loss that is expected to be reclassified into earnings over the next twelve months is $2,809, which will be recorded as an increase to interest expense. |
Fair Value Measurements |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements Fair value is the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. The fair value hierarchy of measurements is categorized into one of three levels based on the lowest level of significant input used: Level 1 - Quoted prices in active markets for identical assets and liabilities at the measurement date. Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 - Unobservable inputs for which there is little or no market data available. These inputs reflect management’s assumptions of what market participants would use in pricing the asset or liability. Our hierarchy for assets and liabilities measured at fair value on a recurring basis is as follows:
Cash equivalents – We value cash equivalents at their current market rates. The carrying value of cash equivalents approximates fair value and maturities are less than three months. Deferred purchase price receivable – We value the deferred purchase price receivable based on a discounted cash flow analysis using unobservable inputs, which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant. Derivative instruments – Our derivative instruments consist of interest rate cap agreements and interest rate swaps. These instruments are valued using inputs such as interest rates and credit spreads. Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments under certain circumstances, such as when there is evidence of impairment. There were no fair value adjustments to such assets during the six month periods ended October 29, 2016 or October 31, 2015. Our debt is not measured at fair value in the condensed consolidated balance sheets. The estimated fair value of our debt as of October 29, 2016 and April 30, 2016 was $1,058,252 and $1,064,752, respectively, as compared to a carrying value of $1,030,836 and $1,038,655 at October 29, 2016 and April 30, 2016, respectively. The fair value of debt was measured using a discounted cash flow analysis based on expected market based yields (i.e., level 2 inputs). The carrying amounts of receivables, net of allowances, accounts payable, and certain accrued and other current liabilities approximated fair value at October 29, 2016 and April 30, 2016. |
Income Taxes |
6 Months Ended |
---|---|
Oct. 29, 2016 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The effective income tax rate from continuing operations for the three months ended October 29, 2016 was 35.9% compared to 36.7% for the three months ended October 31, 2015, and for the six months ended October 29, 2016 was 34.3% compared to 46.7% for the six months ended October 31, 2015. The decrease in the rate for the three and six months ended October 29, 2016 was primarily due to the prior year impact of cash repatriation and transaction-related costs incurred in connection with the acquisition of Animal Health International, Inc. In addition, the current period rates included excess tax benefits from the adoption of ASU No. 2016-09 of $108 and $1,992 for the three and six months ended October 29, 2016, respectively. In the first quarter of fiscal 2016, we approved a one-time repatriation of approximately $200,000 of foreign earnings. This one-time repatriation reduced the overall cost of funding the acquisition of Animal Health International, Inc. In addition, certain foreign cash at Patterson Medical was required to be repatriated as part of the sale transaction. The continuing operations tax impact of $12,300 from the repatriation was recorded during the first six months of fiscal 2016. |
Segment Reporting |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting | Segment Reporting We present three reportable segments: Dental, Animal Health and Corporate. Dental and Animal Health are strategic business units that offer similar products and services to different customer bases. Dental provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists, dental laboratories, institutions, and other healthcare professionals throughout North America. Animal Health is a leading, full-line distributor in North America and the U.K. of animal health products, services and technologies to both the production-animal and companion-pet markets. Our Corporate segment is comprised of general and administrative expenses, including home office support costs in areas such as information technology, finance, legal, human resources and facilities. In addition, customer financing and other miscellaneous sales are reported within Corporate results. Corporate assets consist primarily of cash and cash equivalents, accounts receivable, property and equipment and long-term receivables. We evaluate segment performance based on operating income. The costs to operate the fulfillment centers are allocated to the operating units based on the through-put of the unit. The following table presents information about our reportable segments:
The following table presents sales information by product for all of our reportable segments:
|
Accumulated Other Comprehensive Loss ("AOCL") |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Loss (AOCL) | Accumulated Other Comprehensive Loss ("AOCL") The following table summarizes the changes in AOCL as of October 29, 2016:
The amounts reclassified from AOCL during fiscal 2017 represent gains and losses on cash flow hedges, net of taxes of $527. The impact to the condensed consolidated statements of income was an increase to interest expense of $1,397. |
Legal Proceedings |
6 Months Ended |
---|---|
Oct. 29, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal Proceedings | Legal Proceedings In September 2015, we were served with a summons and complaint in an action commenced in the U.S. District Court for the Eastern District of New York, entitled SourceOne Dental, Inc. v. Patterson Companies, Inc., Henry Schein, Inc. and Benco Dental Supply Company, Civil Action No. 15-cv-05440-JMA-GRB. SourceOne, as plaintiff, alleges that, through its website, it markets and sells dental supplies and equipment to dentists. SourceOne alleges in the complaint, among other things, that we, along with the defendants Henry Schein and Benco, conspired to eliminate plaintiff as a competitor and to exclude them from the market for the marketing, distribution and sale of dental supplies and equipment in the U.S. and that defendants unlawfully agreed with one another to boycott dentists, manufacturers, and state dental associations that deal with, or considered dealing with, plaintiff. Plaintiff asserts the following claims: (i) unreasonable restraint of trade in violation of state and federal antitrust laws; (ii) tortious interference with prospective business relations; (iii) civil conspiracy; and (iv) aiding and abetting the other defendants’ ongoing tortious and anticompetitive conduct. Plaintiff seeks equitable relief, compensatory and treble damages, jointly and severally, punitive damages, interest, and reasonable costs and expenses, including attorneys’ fees and expert fees. Plaintiff has not specified a damage amount in its complaint. We are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial condition. Beginning in January 2016, purported class action complaints were filed against defendants Henry Schein, Inc., Benco Dental Supply Co. and Patterson Companies, Inc. Although there were factual and legal variations among these complaints, each alleged that defendants conspired to foreclose and exclude competitors by boycotting manufacturers, state dental associations, and others that deal with defendants’ competitors. On February 9, 2016, the U.S. District Court for the Eastern District of New York ordered all of these actions, and all other actions filed thereafter asserting substantially similar claims against defendants, consolidated for pre-trial purposes. On February 26, 2016, a consolidated class action complaint was filed by Arnell Prato, D.D.S., P.L.L.C., d/b/a Down to Earth Dental, Evolution Dental Sciences, LLC, Howard M. May, DDS, P.C., Casey Nelson, D.D.S., Jim Peck, D.D.S., Bernard W. Kurek, D.M.D., Larchmont Dental Associates, P.C., and Keith Schwartz, D.M.D., P.A. (collectively, the "putative class representatives") in the U.S. District Court for the Eastern District of New York, entitled In re Dental Supplies Antitrust Litigation, Civil Action No. 1:16-CV-00696-BMC-GRB. Burkhart Dental Supply Company, Inc. was added as a defendant on October 22, 2016. Subject to certain exclusions, the putative class representatives seek to represent all persons who purchased dental supplies or equipment in the U.S. directly from any of the defendants, since August 31, 2008. In the consolidated class action complaint, putative class representatives allege a nationwide agreement among Henry Schein, Benco, Patterson and Burkhart not to compete on price. The consolidated class action complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, compensatory and treble damages, jointly and severally, interest, and reasonable costs and expenses, including attorneys’ fees and expert fees. Putative class representatives have not specified a damage amount in their complaint. While the outcome of litigation is inherently uncertain, we believe the consolidated class action complaint is without merit, and we are vigorously defending ourselves in this litigation. |
Subsequent Event |
6 Months Ended |
---|---|
Oct. 29, 2016 | |
Subsequent Events [Abstract] | |
Subsequent Event | Subsequent Event In the first quarter of fiscal 2006, we extended our exclusive North American distribution relationship with Sirona Dental Systems for Sirona’s CEREC 3D dental restorative system. At that time, we paid a $100,000 distribution fee to extend the existing exclusive relationship for at least a 10-year period beginning in 2007. This distribution fee has been accounted for as an intangible asset that has been amortized since October 2007. Based on our November 2016 decision not to extend sales exclusivity for the full Sirona portfolio of products, we expect to record a pre-tax non-cash impairment charge of approximately $36,000, or approximately $22,000 after taxes or $0.23 per diluted share in our fiscal 2017 third quarter, related to the distribution fee associated with the CEREC product component of this arrangement. |
General (Policies) |
6 Months Ended |
---|---|
Oct. 29, 2016 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of Patterson Companies, Inc. (referred to herein as "Patterson" or in the first person notations "we," "our," and "us") as of October 29, 2016, and our results of operations and cash flows for the periods ended October 29, 2016 and October 31, 2015. Such adjustments are of a normal recurring nature. The results of operations for the periods ended October 29, 2016 and October 31, 2015 are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the financial statements included in our 2016 Annual Report on Form 10-K filed on June 29, 2016. The unaudited condensed consolidated financial statements include the assets and liabilities of PDC Funding Company, LLC ("PDC Funding") and PDC Funding Company II, LLC ("PDC Funding II"), which are our wholly owned subsidiaries and separate legal entities formed under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities established to sell customer installment sale contracts to outside financial institutions in the normal course of their business. The assets of PDC Funding and PDC Funding II would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding or PDC Funding II. |
Fiscal Year End | Fiscal Year End We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. The second quarter of fiscal 2017 and 2016 represents the 13 weeks ended October 29, 2016 and the 13 weeks ended October 31, 2015, respectively. The six months ended October 29, 2016 and October 31, 2015 included 26 and 27 weeks, respectively. Fiscal 2017 will include 52 weeks and fiscal 2016 included 53 weeks of operations. |
Comprehensive Income | Comprehensive Income Comprehensive income is computed as net income including certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income are foreign currency translation adjustments and the effective portion of cash flow hedges, net of tax. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" and issued subsequent amendments to the initial guidance in August 2015, March 2016, April 2016 and May 2016 within ASU 2015-14, ASU 2016-08, ASU 2016-10 and ASU 2016-12, respectively. ASU No. 2014-09 supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of this pronouncement by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption is permitted, but not before the original effective date, which for annual periods was December 15, 2016. We are evaluating the impact of adopting this pronouncement. In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory." ASU 2015-11 requires inventory measured using any method other than LIFO or the retail inventory method to be subsequently measured at the lower of cost or net realizable value, rather than at the lower of cost or market. Subsequent measurement of inventory using the LIFO and retail inventory method is unchanged. We are required to adopt the new pronouncement in the first quarter of fiscal 2018, and plan to do so at that time. Early adoption is permitted. We are evaluating the effect of adopting this pronouncement, but do not, at this time, anticipate a material impact to our financial statements once implemented. In January 2016, the FASB issued ASU No. 2016-01 "Financial Instruments- Recognition and Measurement of Financial Assets and Financial Liabilities (Subtopic 825-10)", which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments, including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. We are required to adopt the ASU No. 2016-01 in the first quarter of fiscal 2019, with early adoption permitted. We are evaluating the impact of adopting this pronouncement. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)," which requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases, as well as requires additional qualitative and quantitative disclosures. We are required to adopt ASU 2016-02 in the first quarter of fiscal 2020, with early adoption permitted. We are evaluating the impact of adopting this pronouncement. In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting." ASU No. 2016-09 eliminates the additional paid-in capital pool concept and requires that excess tax benefits and tax deficiencies be recorded in the income statement when awards are settled. ASU No. 2016-09 also addresses simplifications related to statement of cash flows classification, accounting for forfeitures, and minimum statutory tax withholding requirements. During the first quarter of fiscal 2017, we adopted ASU No. 2016-09. As a result of this adoption, we recognized $108 and $1,992 of excess tax benefits related to share-based payments in our provision for income taxes for the three and six months ended October 29, 2016, respectively. These items were historically recorded in additional paid-in capital. In addition, for the six months ended October 29, 2016, cash flows related to excess tax benefits are classified as an operating activity along with other income tax cash flows. Prior periods have not been adjusted. Cash paid on employees' behalf related to shares withheld for tax purposes continues to be classified as a financing activity. Our share-based compensation expense in each period continues to reflect estimated forfeitures. |
General (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Computation of Basic and Diluted Earnings Per Share (EPS) | The following table sets forth the computation of the weighted average shares outstanding used to calculate basic and diluted earnings per share ("EPS"):
|
Derivative Financial Instruments (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Interest Rate Contracts Included in Condensed Consolidated Balance Sheets | The following presents the fair value of derivative instruments included in the condensed consolidated balance sheets:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of Interest Rate Contracts on Condensed Consolidated Statements of Income and Other Comprehensive Income (OCI) | The following table presents the pre-tax effect of derivative instruments in cash flow hedging relationships on the consolidated statements of income and other comprehensive income ("OCI"):
|
Fair Value Measurements (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and Liabilities Measured at Fair Value on Recurring Basis | Our hierarchy for assets and liabilities measured at fair value on a recurring basis is as follows:
|
Segment Reporting (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Information about Reportable Segments | The following table presents information about our reportable segments:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sales Information by Product | The following table presents sales information by product for all of our reportable segments:
|
Accumulated Other Comprehensive Loss ("AOCL") (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 29, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Accumulated Other Comprehensive Loss | The following table summarizes the changes in AOCL as of October 29, 2016:
|
General - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Oct. 29, 2016 |
Oct. 31, 2015 |
Oct. 29, 2016 |
Oct. 31, 2015 |
|
Accounting Policies [Abstract] | ||||
Income tax expense related to cash flow hedges | $ 265 | $ 265 | $ 527 | $ 350 |
Securities excluded from calculation of diluted earnings per share (in shares) | 1,453 | 899 | 1,218 | 899 |
Excess tax benefit from share-based payments recognized | $ 108 | $ 1,992 |
General - Computation of Basic and Diluted Earnings Per Share (EPS) (Detail) - shares shares in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Oct. 29, 2016 |
Oct. 31, 2015 |
Oct. 29, 2016 |
Oct. 31, 2015 |
|
Earnings Per Share [Abstract] | ||||
Denominator for basic earnings per share – weighted average shares (in shares) | 95,290 | 98,525 | 95,510 | 98,981 |
Effect of dilutive securities - stock options, restricted stock and stock purchase plans (in shares) | 614 | 660 | 628 | 693 |
Denominator for diluted earnings per share – weighted average shares (in shares) | 95,904 | 99,185 | 96,138 | 99,674 |
Discontinued Operations (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended |
---|---|---|---|
Aug. 31, 2015 |
Oct. 31, 2015 |
Oct. 31, 2015 |
|
Discontinued Operations and Disposal Groups [Abstract] | |||
Proceeds from the sale including working capital adjustment | $ 716,886 | ||
Percentage of common units obtained | 10.00% | ||
Ratio of acquirer cash inflows to cash outflows at which common units obtained begin participating in distributions | 2.5 | ||
Transition services agreement, period of involvement | 24 months | ||
Net sales from discontinued operations | $ 37,693 | $ 168,504 |
Derivative Financial Instruments - Fair Value of Interest Rate Contracts Included in Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands |
Oct. 29, 2016 |
Apr. 30, 2016 |
---|---|---|
Derivatives, Fair Value [Line Items] | ||
Interest rate contracts, assets, fair value | $ 790 | $ 816 |
Interest rate contracts, liabilities, fair value | 790 | 816 |
Other Noncurrent Assets [Member] | Interest Rate Contracts [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Interest rate contracts, assets, fair value | 790 | 816 |
Other Noncurrent Liabilities [Member] | Interest Rate Contracts [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Interest rate contracts, liabilities, fair value | $ 790 | $ 816 |
Derivative Financial Instruments - Effect of Interest Rate Contracts on Condensed Consolidated Statements of Income and Other Comprehensive Income (OCI) (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Oct. 29, 2016 |
Oct. 31, 2015 |
Oct. 29, 2016 |
Oct. 31, 2015 |
|
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Accumulated other comprehensive loss expected to be reclassified into earnings | $ (2,809) | |||
Interest Rate Swap [Member] | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Accumulated other comprehensive loss expected to be reclassified into earnings | $ (702) | $ (703) | $ (1,397) | $ (1,405) |
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands |
Oct. 29, 2016 |
Apr. 30, 2016 |
---|---|---|
Assets: | ||
Cash equivalents | $ 3,506 | $ 14,609 |
Deferred purchase price receivable | 118,059 | 108,837 |
Derivative instruments | 790 | 816 |
Total assets | 122,355 | 124,262 |
Liabilities: | ||
Derivative instruments | 790 | 816 |
Fair Value, Inputs, Level 1 [Member] | ||
Assets: | ||
Cash equivalents | 3,506 | 14,609 |
Deferred purchase price receivable | 0 | 0 |
Derivative instruments | 0 | 0 |
Total assets | 3,506 | 14,609 |
Liabilities: | ||
Derivative instruments | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Deferred purchase price receivable | 0 | 0 |
Derivative instruments | 790 | 816 |
Total assets | 790 | 816 |
Liabilities: | ||
Derivative instruments | 790 | 816 |
Fair Value, Inputs, Level 3 [Member] | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Deferred purchase price receivable | 118,059 | 108,837 |
Derivative instruments | 0 | 0 |
Total assets | 118,059 | 108,837 |
Liabilities: | ||
Derivative instruments | $ 0 | $ 0 |
Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands |
Oct. 29, 2016 |
Apr. 30, 2016 |
---|---|---|
Fair Value Disclosures [Abstract] | ||
Estimated fair value of debt | $ 1,058,252 | $ 1,064,752 |
Carrying value of debt | $ 1,030,836 | $ 1,038,655 |
Income Taxes (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Oct. 29, 2016 |
Oct. 31, 2015 |
Aug. 01, 2015 |
Oct. 29, 2016 |
Oct. 31, 2015 |
|
Income Tax Disclosure [Abstract] | |||||
Effective income tax rate | 35.90% | 36.70% | 34.30% | 46.70% | |
Excess tax benefit from share-based payments recognized | $ 108 | $ 1,992 | |||
Repatriation of foreign earnings | $ 200,000 | ||||
Tax impact of repatriation of foreign earnings | $ 12,300 |
Segment Reporting - Sales Information by Product (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Oct. 29, 2016 |
Oct. 31, 2015 |
Oct. 29, 2016 |
Oct. 31, 2015 |
|
Segment Reporting Information [Line Items] | ||||
Net sales | $ 1,418,241 | $ 1,389,210 | $ 2,750,677 | $ 2,532,080 |
Consumable [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 1,112,232 | 1,087,489 | 2,188,453 | 1,982,796 |
Equipment and Software [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 217,194 | 207,809 | 378,140 | 361,292 |
Other [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | $ 88,815 | $ 93,912 | $ 184,084 | $ 187,992 |
Accumulated Other Comprehensive Loss ("AOCL") - Additional Information (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Oct. 29, 2016 |
Oct. 31, 2015 |
Oct. 29, 2016 |
Oct. 31, 2015 |
|
Equity [Abstract] | ||||
Income tax expense related to cash flow hedges | $ 265 | $ 265 | $ 527 | $ 350 |
Increase in interest expense | $ 1,397 |
Subsequent Event (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | |
---|---|---|
Jan. 28, 2017 |
Jul. 30, 2005 |
|
Subsequent Events [Abstract] | ||
Distribution fee paid | $ 100,000 | |
Distribution relationship term extension | 10 years | |
Distribution Rights [Member] | Scenario, Forecast [Member] | Subsequent Event [Member] | ||
Subsequent Event [Line Items] | ||
Non-cash impairment charge before tax | $ 36,000 | |
Non-cash impairment charge after tax | $ 22,000 | |
Non-cash impairment charge per diluted share (in USD per share) | $ 0.23 |
&$ >RZ='R-<2)O;93C,,_?'3+),8^AWO]/3I2.[
M' #WHWZ5N>BPMS)$)U> 'L&\W!JOES)[1 7<<<7V=RB$/0HQ!Q<<',5^7]4
MT;P6HGXQY+9GIH>2Z3C8O&QA6&BP;=$%*&;QY'YK%!T79EZ1,*Q(V&7SC8W3
M@+'[-SJXN)PS0 A!*'+3,VO[HXLDT#['GQW6;6/@UCJ!86W!RI"E$=N^-R
M[>WDI6STMGX8'8[D3[@]DGT97Z+9"AG&UVBVT4>X3_>+^3D]BA]I=U@Y2-4*K#!W7$/(ET/]SDXM"TETQ=5_K8K6\:>>Y_11A^REC\ U!+
M P04 " !)A(=)/Z2Z"5X# 0$0 &0 'AL+W=O%7I ?O=@KMSGUSS \:9&$%
M;T6J>S$PM_L#@*[)+-Z.5/=C.!93<&K-PE:(VPK'I@R,2P#=A(09B@NFYB>0
MCP*?-)#R.!Q%K@:D(+Y=H/B$H7K$1!82,5ZNL7VY,H)ZP8A%(0'HBD)B^.Q@
M>G;$%A*&C7_%RF?XSF=\;(+U,=]KD&\?,SX0&/2Z0!^$!%C3()LG(7PD,!@)
M8B2JA08URYG;!85/! 8305BL(H:O:';%CF9X"S%H(8$^%^O4:I!O80??NPSZ
M3 27)3B^>/D5BY?CSY>QR5N<#R&)Z<<.C-W28&'DPGO/Q
M-O1.WLH.R4[^3,I=6E3.BZJ;%[SN/6RK5"T;*7+;O)SN9;(93C*YK=O#L#DN
M^Q?V_J16!_W[P_ CR.P_4$L#!!0 ( $F$ATD%+])V] $ %,& 9
M>&PO=V]R:W-H965T)<*UO]!#7=2X+8I2(%/I;;L'\MP["1^%4:MC"+#\V5N52:
ML??U&9UT::YG]*E6[D)G&**%=IU9QKEW:9K]X?\!4$L! A0#% @ 282'
M24PZ:/JV 0 %!< !, ( ! %M#;VYT96YT7U1Y<&5S
M72YX;6Q02P$"% ,4 " !)A(=)2'4%[L4 K @ "P
M@ 'G 0 7W)E;',O+G)E;'-02P$"% ,4 " !)A(=)XPZ8X8H! 6%@
M&@ @ '5 @ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4 " !)A(=)I*('2;(" #5"0 $ @ &7!
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( $F$ATFY&&^T/P$ &D# 1
M " 7<' !D;V-0
B.TFRZ[_#R2)(.6OEDM)=.&V-S"EP23ZC/\-7)
M]Z=5'IF=O?ZV-RTHB4/ OC<7O*],3(;/QCN0XBD7)/&LO;$RI>AU](H+YH)A
M,FEQ\OW/;$;%K6]I)@/IW)6(8*@!>7"1B Y42:\TB=(S)V4RTNJ3RA,WD7'S
MEDTB9O3M/B1.!P5D\,BM5REJ'66>D<")# *I-K^4#W(YE9Z=7-4P#[[U!R00V8?T -5A)<'4@*;!]U
M*3,992W5YI1)NALJ:B;P>(QMV &2*6RY84ZM?5=^0/*H,UE-I
M &7-#K""^3@LG9 'ST)0%+P[ESH">&(>V!21>LE(KJVG 1QA=G.C>CM1=V>B
M+0W1XL!PPA4#=)(% 'K<=O?G'%)ITXF+@MALD)%ZRV$*\Z+K-)%G,$L3]=YH2Z5&] 1 I\:@&WTOB1S#%?#5=3)
M&9]S8!+8,:;J,RPM!)-@,NII3Q;,]P9R?A"6#G UUI!HDR9: DL[FRRP&Y[W#5LV&+,!+JA3NIE%(Y
MKF3!?(M0Z2S >Y3F.
M\$[)M-KAC>2QL @COO^15IX\O&5@EDKQY'5WJF#X"7H<.03/%FE03E"]&0XC
MWT,AU.J7P,HJ@1+V<<&8U?U@R8MRK #LAD6Y]9[ _AY.KG((Y,/7B9WYBKO9*)?72G:*7;OQ4-XUP)W2<^N+S!(9(9ZFDVV=<(+1<
M(@%*/ :Y56G;'\,X_H:AI)?L(?7,8>^T-[P\'PY/[2'\ _47[R;Q(O$Z1/'J
MFX8UU+8_L_?B=?"[NI\3^*T6F=KML23]HN4XAJ,O;_Y0JB-2%)1$:GV)EJXQ
M-/4I*Q(I$JE#%RG3Z1D=AYHVD$R13.F3J8$QU.A4'8A,U;7M9;?^+!2FTN*2
M U2N]=4>QJ%L#^^T8M#^U.IZ8PZU;F6\EG E
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MY-Y!=LZ*X.[SX\(JBD-NG]]6BY6"F'V2J^\_;7WM_KV[3[^91%B,EN6
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M,K$=CZC]Q[0VW"G:?N[@V@7)GB:3AY;V4IM"YG;T.ZR#E#6473+L8*DU3&<3DV5L@@GUQN9Z_/ MS:QQ_*X%Q*N^P^2
MM+O(X5I-S*E@D] '6(9G,I72/8]$# ^+6_]='1VV1T7[T?E6?%+<58 (OVT+[(,
MC'!.@['&
__CK&(SDS$(O%AO#P6K4ITGC*=/\]YJK21Y9,I00C2)*+
M:/$SV+ ,-D[7UF0UE8+7 ^6#";Y'SK=E!"0IA(X8PT!42KB/,+"@[2B\M!X/B(83
MD3'FXEJR!/J).2^12LL=(\+B6T]HD Q@1OM@LP;W[CSC@2F=(?CP!A!I+?<;)J:X=Z*W)!'A
M64>K!99IA-B ,R>T""E);ICQRM6#;49M32?N@^@V28.Q#BX%7!0C,M.$22HL
M)@XX6'-C:D1+RO2!DA[#A_.C&WMK<= T:Y:YS\J ?XR&> XZD:TUV+6BH009
MUA3:M 4K%.Q'6IL$2399:*FL!&R2(=Z@5D
26-$*MJ@Y87LRR7EE?/X8X]^!/+?*%]4"D'_?\J
MAZV%+ V-J2LW@30HU7-<;=51.5IA>8('!GEACAWJO#S*K:]:)_F$&?
MF$P4\U8/KQ>^.YO*:NA%1F?"?\@*@,][QCB43D[.^+RLVR9]F&S:,"885"Y/
MT2SD40#TC%7JUF-7C7K> S_3MC57(M;F8B2+X*&+[@;G(\[/?/KIR+R_[EF6GWS<&P,^A>G9G.\,*YZIY;@Z-?'RQ,
MEE5/,%*>R!S&E::?EQ*3\M(QHKJ/;HFC]WWLZ#]/>NI>\]Y'W_
M$FP>B1AGOC3A3<9+II%8CBUM,A*+)"5E^GZLB!N_9RIMPV +VS",!V-61+9.
MLHODMP^NBV"L!"^Z\5PV2F.@?1RS-/"2F"53GK!P,A$1BSV8'H^ -.$X=>$W
M'"H6T:WG ELF(1M[>!U2S4UC@#*X9\1C$1?/ACMOO3%1BI^V-Q,\/[WV],@W5O2+GL('I]+
C6/R1PAV7MUC(O;@(J!@@
MJ;Z*R2]'5Q=6QQS\P_KWMXLCYHWA"^XFQZ>]B^Z5Y0Q[@\[YY47?<1S[W#D_
ML\\&YZ?=X7GWZ-<'I*^2\8EJZJM6[M'Z^59OKJU